Biotech & Research
Six leadership editions
When Your Lead Scientist Leaves
Your most advanced programme has a decade of experimental rationale behind it. How much of that rationale would survive if your principal scientist accepted an offer next month?
What's Changing in Your Programme Capital Story
Your next €50M of capital. The burn-to-readout forecast you sign. The thesis your specialist-fund anchor can recite back. Three questions that look separate, but are actually one. A briefing for CFOs at mid-market European biotech firms.
What's Changing in How You Run Your Programmes
Your trial economics are drifting. Your senior regulatory and CMC leads are five years from retirement. Your milestone cycles have not moved in a decade. Three problems that look separate, but are actually one. A briefing for operations leaders at mid-market biotech firms.
What's Changing in the Specialist Bench You're Building
Your senior regulatory leads are watching. Your junior pathway has quietly collapsed. Your 2030 specialist bench is being shaped by decisions you were not invited to. A briefing for Chief Human Resources Officers at mid-market European specialty biotech, CDMO, and diagnostic services firms.
The Term Sheet That Cooled on Commercial Readiness
Your partner's DD team is asking commercial questions your team cannot answer on the call. Your field team is working harder with less to show. Your KOL relationships live in two people's heads. A briefing for commercial leaders at mid-market European biotechs.
What's Changing in the Discovery Moat You Encode
Your firm holds twenty years of programme-execution intelligence in three or four senior heads. Your AI-native competitor has shiny generative chemistry. Your scorecard is system uptime and validation cycle time, and neither is the 2026 question. A briefing for CTOs and Heads of Digital R&D at mid-market European specialty biotechs, CDMOs, and diagnostics firms.